Search research articles
Contact Us
Filters
Showing results (21-30 of 177) with videos related to
Page
of 18
Sort By:
International Journal of Cancer
|
May 4, 1995
Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes
F Vikhanskaya, M D'Incalci, M Broggini
Current Medicinal Chemistry. Anti-Cancer Agents
|
May 12, 2004
New molecules and strategies in the field of anticancer agents
S Marchini, M D'Incalci, M Broggini
Current Medicinal Chemistry
|
January 20, 2012
RAS/RAF/MEK inhibitors in oncology
P Rusconi, E Caiola, M Broggini
European Journal of Cancer & Clinical Oncology
|
March 1, 1983
Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice
M Broggini, P Ghersa, M G Donelli
The Lancet. Oncology
|
July 8, 2015
Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors
V Torri, M Broggini, M C Garassino
Nucleic Acids Research
|
October 25, 1991
O6-methylguanine inhibits the binding of transcription factors to DNA
M Bonfanti, M Broggini, C Prontera, et al.
Recenti Progressi in Medicina
|
September 1, 1986
[New etiopathologic and therapeutic perspectives in ureteral colic. Evaluation of clinical experience with diclofenac sodium and indomethacin]
E Grossi, U Garagiola, A Marconi, et al.
Experimental Cell Research
|
September 15, 1996
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53
F Vikhanskaya, E Erba, M D'Incalci, et al.
Lancet (London, England)
|
January 1, 1983
Transplacental passage of doxorubicin
M d'Incalci, M Broggini, M Buscaglia, et al.
British Medical Journal (Clinical Research Ed.)
|
April 7, 1984
Diclofenac sodium in biliary colic: a double blind trial
M Broggini, E Corbetta, E Grossi, et al.
Page
of 18
Search research articles
Search
Showing results (21-30 of 177) with videos related to
Sort By:
Page
of 18
International Journal of Cancer
|
May 4, 1995
Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes
F Vikhanskaya, M D'Incalci, M Broggini
Current Medicinal Chemistry. Anti-Cancer Agents
|
May 12, 2004
New molecules and strategies in the field of anticancer agents
S Marchini, M D'Incalci, M Broggini
Current Medicinal Chemistry
|
January 20, 2012
RAS/RAF/MEK inhibitors in oncology
P Rusconi, E Caiola, M Broggini
European Journal of Cancer & Clinical Oncology
|
March 1, 1983
Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice
M Broggini, P Ghersa, M G Donelli
The Lancet. Oncology
|
July 8, 2015
Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors
V Torri, M Broggini, M C Garassino
Nucleic Acids Research
|
October 25, 1991
O6-methylguanine inhibits the binding of transcription factors to DNA
M Bonfanti, M Broggini, C Prontera, et al.
Recenti Progressi in Medicina
|
September 1, 1986
[New etiopathologic and therapeutic perspectives in ureteral colic. Evaluation of clinical experience with diclofenac sodium and indomethacin]
E Grossi, U Garagiola, A Marconi, et al.
Experimental Cell Research
|
September 15, 1996
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53
F Vikhanskaya, E Erba, M D'Incalci, et al.
Lancet (London, England)
|
January 1, 1983
Transplacental passage of doxorubicin
M d'Incalci, M Broggini, M Buscaglia, et al.
British Medical Journal (Clinical Research Ed.)
|
April 7, 1984
Diclofenac sodium in biliary colic: a double blind trial
M Broggini, E Corbetta, E Grossi, et al.
Page
of 18